Nanobiotix S.A.
No SEC Form 4 filings for $NBTX in the last 30 days.
See all $NBTX insider activity →Nanobiotix (NBTX) reported 79% one-year locoregional control in a Phase 1 study of NBTXR3 with repeat radiation for inoperable lung cancer. All 24 patients completed treatment with no product-related severe adverse events, but eight had Grade 3 and two had Grade 5 radiation-related events. The study's small size and lack of control group limit conclusions.
Tom Lee of Fundstrat told CNBC on June 9 that market jitters are tied to the run-up to SpaceX’s $75 billion Nasdaq 100 IPO and ongoing tech capital raises, but he views consolidation as healthy. The article screens small caps with 5-year sales growth >30% and lists 12 hedge-fund favorites (data June 15), including Nanobiotix (€42.1m cash; €86.1m follow-on) and Agilon (Barclays $81; Benchmark $95).
Nanobiotix reported its voting rights as of May 31, 2026: 50,807,903 shares outstanding, with 54,304,858 total theoretical voting rights and 54,282,740 exercisable voting rights. The filing cites French Commercial Code L.233-8 II and AMF rules on gross and net voting-right calculations, relevant for threshold monitoring on Euronext Paris and Nasdaq.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning NBTX (Nanobiotix S.A.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent NBTX coverage spans financial news, technology and regulation.
Positive early efficacy may boost speculative interest, but safety concerns and small uncontrolled study limit upside.
Fresh financing plus updated clinical/regulatory trial mechanics can shift perceived probability-weighted timelines and funding risk for NBTX.
Voting-rights disclosure can affect ownership-threshold monitoring and proxy/meeting mechanics, but it is not an operating catalyst.
Index/segment inclusion is likely to support near-term sentiment and flows, but it is not a fundamental operating update.
Equity raise likely reduces near-term dilution overhang but can pressure the stock via issuance/dilution expectations.
AlphAI scores every news story that mentions NBTX with an AI model for sentiment and relevance, and aggregates insider trades from Nanobiotix S.A.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Nanobiotix (NBTX) reported 79% one-year locoregional control in a Phase 1 study of NBTXR3 with repeat radiation for inoperable lung cancer. All 24 patients completed treatment with no product-related severe adverse events, but eight had Grade 3 and two had Grade 5 radiation-related events. The study's small size and lack of control group limit conclusions.
2 min readTom Lee of Fundstrat told CNBC on June 9 that market jitters are tied to the run-up to SpaceX’s $75 billion Nasdaq 100 IPO and ongoing tech capital raises, but he views consolidation as healthy. The article screens small caps with 5-year sales growth >30% and lists 12 hedge-fund favorites (data June 15), including Nanobiotix (€42.1m cash; €86.1m follow-on) and Agilon (Barclays $81; Benchmark $95).
6 min readNanobiotix reported its voting rights as of May 31, 2026: 50,807,903 shares outstanding, with 54,304,858 total theoretical voting rights and 54,282,740 exercisable voting rights. The filing cites French Commercial Code L.233-8 II and AMF rules on gross and net voting-right calculations, relevant for threshold monitoring on Euronext Paris and Nasdaq.
1 min readNanobiotix said it has been added to Euronext’s Tech Leaders segment and Tech Leaders Index, a Euronext initiative launched in 2022 to boost visibility of European high-growth technology firms with international investors. The company, a late-clinical biotech focused on physics-based nanotherapeutics, is listed on Euronext Paris and Nasdaq.
2 min readNanobiotix said it has closed its global offering, including the underwriters’ option for additional shares/ADSs. After full option exercise, it issued 2,218,467 ordinary shares (225,373 ADSs plus 33,805 additional ADSs) and 345,099 pre-funded warrants, raising about $100 million (€86.1 million) gross. Net proceeds will fund JNJ-1900 (<10%), Nanoprimer (50–60%), and general purposes (30–40%).
2 min readNanobiotix S.A. (NASDAQ:NBTX) experienced a significant 75.8% decrease in short interest during February, with total short interest falling to 15,389 shares. Analysts generally hold a "Moderate Buy" consensus rating with an average price target of $20.00, though the stock recently traded at $38.65, well above analyst targets. Institutional investors have also been adjusting their holdings, with Royal Bank of Canada notably increasing its position.
4 min readPARIS and CAMBRIDGE, Mass., Nov. 24, 2025 ( GLOBE NEWSWIRE ) -- NANOBIOTIX ( Euronext: NANO -- NASDAQ: NBTX - the ''Company'' ) , a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, ...
4 min readIt has grown wildly, and it could keep growing.
3 min readFour new patent applications filed that aim to expand the Curadigm Nanoprimer platform intellectual property portfolio and support an initial proprietary internal pipeline of Nanoprimer products in addition to external collaborations
2 min readPARIS and CAMBRIDGE, Mass., Nov. 13, 2025 ( GLOBE NEWSWIRE ) -- NANOBIOTIX ( Euronext: NANO -- NASDAQ: NBTX - the ''Company'' ) , a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, ...
4 min read
